Makers Laboratories Ltd Upgraded to Hold by MarketsMOJO on Technical and Financial Improvements

Technical Trends Spark Upgrade

The primary catalyst for the rating change was a marked improvement in the technical outlook for Makers Laboratories. The technical grade shifted from mildly bullish to bullish, signalling stronger momentum in the stock’s price action. Key technical indicators underpinning this upgrade include a bullish stance in Bollinger Bands on both weekly and monthly charts, and daily moving averages that continue to support upward price movement.

While the MACD remains mildly bearish on a weekly basis, it is bullish on the monthly timeframe, suggesting that longer-term momentum is gaining strength. The KST indicator presents a mixed picture, mildly bearish weekly but mildly bullish monthly, indicating some short-term volatility but an overall positive trend. Dow Theory assessments also reflect a mildly bullish weekly trend, though no clear monthly trend has emerged yet.

These technical signals have contributed to a 6.00% gain in the stock price on the day of the upgrade, with the share price rising from ₹151.70 to ₹160.80, and intraday highs touching ₹166.95. This price action is supported by a 52-week high of ₹186.70 and a low of ₹109.00, showing the stock’s recovery potential within its trading range.

Financial Trend: Quarterly Performance Boosts Confidence

Makers Laboratories reported a strong quarter in Q4 FY25-26, with net sales reaching a quarterly high of ₹35.75 crores and PBDIT climbing to ₹5.27 crores. The company’s debtors turnover ratio also improved significantly, registering the highest half-yearly figure at 7.08 times, indicating efficient receivables management and improved cash flow.

Despite these positive quarterly results, the company’s profitability over the past year has been under pressure, with profits declining by 71.7%. This sharp fall in profits tempers enthusiasm somewhat, but the recent quarterly rebound suggests potential for stabilisation going forward.

Return on Equity (ROE) stands at a modest 3.2%, reflecting fair but limited profitability relative to shareholder funds. The average ROE over the last five years is 4.67%, underscoring the company’s challenges in generating strong returns consistently. Operating profits have contracted at a CAGR of -7.99% over the past five years, highlighting weak long-term fundamental strength.

Valuation: Discounted Pricing Supports Hold Rating

Makers Laboratories is currently trading at a Price to Book Value of 1.3, which is considered fair and notably at a discount compared to its peers’ average historical valuations. This valuation discount provides a cushion for investors, especially given the company’s micro-cap status and the volatility often associated with smaller pharmaceutical firms.

The stock’s year-to-date return of 36.10% significantly outperforms the Sensex, which has declined by 7.97% over the same period. Over the last three years, Makers Labs has delivered a 34.67% return, again surpassing the Sensex’s 19.34% gain. However, the five-year return of -19.96% lags behind the Sensex’s 44.25% growth, reflecting the company’s inconsistent longer-term performance.

Quality Assessment: Mixed Signals from Financial Metrics

The company’s quality grade remains cautious due to its weak long-term fundamentals. While recent quarterly results are encouraging, the overall financial trend shows deteriorating operating profits and low profitability per unit of equity. The promoter group remains the majority shareholder, which can be a stabilising factor but also raises governance considerations for some investors.

Given these factors, the Mojo Score stands at 54.0, with a Mojo Grade upgraded to Hold from Sell. This reflects a balanced view that acknowledges recent improvements but also recognises the risks inherent in the company’s financial and operational profile.

Technical Outlook and Market Sentiment

The upgrade is also supported by a more bullish technical outlook, which has improved investor sentiment. The stock’s daily moving averages are bullish, and the Bollinger Bands on weekly and monthly charts confirm upward momentum. These technical factors suggest that the stock may continue to gain in the near term, supported by positive market dynamics within the Pharmaceuticals & Biotechnology sector.

However, some indicators such as the weekly MACD and KST remain mildly bearish, signalling that short-term volatility could persist. Investors should monitor these signals closely alongside fundamental developments.

Conclusion: Hold Rating Reflects Balanced Outlook

The upgrade of Makers Laboratories Ltd to a Hold rating reflects a nuanced assessment of the company’s current position. Improved technical indicators and a strong quarterly performance have boosted confidence, while valuation metrics suggest the stock is attractively priced relative to peers. However, weak long-term profitability and operating profit contraction remain concerns that prevent a more bullish stance.

Investors considering Makers Laboratories should weigh the recent positive momentum against the company’s historical challenges. The stock’s micro-cap status and sector dynamics offer both opportunities and risks, making it suitable for investors with a moderate risk appetite who are looking for potential recovery plays within Pharmaceuticals & Biotechnology.

Overall, the Hold rating signals a cautious optimism, recommending investors to monitor developments closely while recognising the stock’s potential for further gains if financial trends continue to improve.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →